Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-41386
Abozguia, K; Elliott, P; McKenna, W; Phan, T T; Nallur Shivu, G; Ahmed, I; Maher, A R; Kaur, K; Taylor, J; Henning, A; Ashrafian, H; Watkins, H; Frenneaux, M (2010). Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation, 122(16):1562-1569.
- Registered users only
View at publisher
In symptomatic hypertrophic cardiomyopathy, perhexiline, a modulator of substrate metabolism, ameliorates cardiac energetic impairment, corrects diastolic dysfunction, and increases exercise capacity. This study supports the hypothesis that energy deficiency contributes to the pathophysiology and provides a rationale for further consideration of metabolic therapies in hypertrophic cardiomyopathy.
0 downloads since deposited on 05 Jan 2011
0 downloads since 12 months
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Institute of Biomedical Engineering|
610 Medicine & health
|Date:||4 October 2010|
|Deposited On:||05 Jan 2011 08:40|
|Last Modified:||27 Nov 2013 18:34|
|Publisher:||Lippincott Wiliams & Wilkins|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page